Journals / Turkish Neurosurgery / 2019 / Cilt: 29 - Sayı: 2

Vagal Nerve Stimulation has Robust Effects on Neuropsychiatric Assessment in Resistant Epilepsy: A Clinical Series with Clinical Experiences

Pages
213–221
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The best approach for comparing and evaluating QoL in PREpatients may be the QoLiE-31-P inventory, which can be adapted and used in epilepsy centers to evaluate energy, mood, dailyactivity, cognition, medication effects, seizure worry and overall QoL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To evaluate the resistant epileptic patients who had vagal nerve stimulation (VNS) devices implanted over five years, and toevaluate the neuropsychological aspects of VNS.MATERIAL and METHODS: Patients with pharmacoresistant epilepsy (PRE) were followed from 2012 to 2017.
📊
Key Findings & Data:The patients’ quality of life (QoL) was calculated just before and 12th / 24th months after VNSimplantation.
💡
Conclusion & Impact:The best approach for comparing and evaluating QoL in PREpatients may be the QoLiE-31-P inventory, which can be adapted and used in epilepsy centers to evaluate energy, mood, dailyactivity, cognition, medication effects, seizure worry and overall QoL.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Özet

AIM: To evaluate the resistant epileptic patients who had vagal nerve stimulation (VNS) devices implanted over five years, and toevaluate the neuropsychological aspects of VNS.MATERIAL and METHODS: Patients with pharmacoresistant epilepsy (PRE) were followed from 2012 to 2017. Totally sevenpatients were found eligible for VNS in this period. In the pre-surgical period, patients were neuro-psychiatrically assessed byan independent psychiatric committee for mental status, which included assessment of intelligence quotient (IQ), Wechsler adultintelligence scale-revised (WAIS-R) IQ, Stroop test and mini-mental state examination (MMSE), Hamilton depression scale (HDS)and the Beck anxiety inventory (BAI).RESULTS: The positive effects of VNS on patients’ well-being and neuropsychiatric status may be the most as important as thetreatment’s cost effectiveness. The patients’ quality of life (QoL) was calculated just before and 12th / 24th months after VNSimplantation. The pre-VNS scores for Quality of Life in Epilepsy (QoLiE-31-P) ranged from 14‒59, and average score was 37.14.Thepost-VNS scores ranged from 31‒72, and the average score was 52.86.CONCLUSION: VNS has intense effects on QoL of epileptic patients. The best approach for comparing and evaluating QoL in PREpatients may be the QoLiE-31-P inventory, which can be adapted and used in epilepsy centers to evaluate energy, mood, dailyactivity, cognition, medication effects, seizure worry and overall QoL.

🔖

Cite This Article

EKMEKÇİ, H., KAPTAN, H. (2019). Vagal Nerve Stimulation has Robust Effects on Neuropsychiatric Assessment in Resistant Epilepsy: A Clinical Series with Clinical Experiences. Turkish Neurosurgery, Cilt: 29 - Sayı: 2, 213–221. https://ajindex.com/articles/404432

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bazil CW, Morrell MJ, Pedley TA: Epilepsy. In: Rowland LP (ed), Merritt’s Neurology, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:990–1008 2. Cramer JA: Exploration of changes in health-related quality of life after 3 months of vagus nerve stimulation. Epilepsy Behav 2(5):460-465,2001 3. Ekmekci H, Kaptan H: Vagal nerve stimulation. Macedon J of Med Sci 5(3):391-394,2017 4. Ergene E, Behr PK, Shih JJ: Quality of life assessment in patients treated with vagus nerve stimulation. Epilepsy Behav 2(3):284-287,2001 5. Goldenberg MM: Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. Pharmacy and Theurapeutics 35(7):392–415,2010 6. Goldstein MA, Silverman ME: Neuropsychiatric assessment. Psychiatr Clin North Am 28(3):507-547,2005 7. Groves DA, Brown VJ: Vagal nerve stimulation: A review of its applications and potential mechanisms that mediate its clinical effects. Neuroscience and Bio behavioral Reviews 29: 493-500,2005 8. Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 59(6 Suppl 4):S3-14,2002 9. Janszky J, Hoppe M, Behne F, I Tuxhorn, H, W Pannek, A Ebner: Vagus nerve stimulation: Predictors of seizure freedom. J Neurol Neurosurg Psychiatry 76(3):384–389,2005 10. Krist V, Robrecht R, Naulaerts J, et al: Vagus nerve stimulation. 25 years later! What do we know about the effects on cognition? Neuroscience & Biobehavioral Reviews 45:63– 71,2014 11. Kwan P, Arzimanoglou A, Berg AT, De Vogelaere F, Thiery E, Van Roost D, Aldenkamp B, Miatton M, Boon P: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6):1069-1077,2010 12. McNamara JO: Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1999:461-486 13. Morris GL III, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C: Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81(16):1453-1459,2013 14. Oliveira TVHF, Francisco AN, Junior ZD, Stebel SL: The role of vagus nerve stimulation in refractory epilepsy. Arquivos de Neuro – Psiquiatria 75(9):657-666,2017 15. Penry JK, Dean JC: Prevention of intractable partial seizures by intermittent vagal stimulation in humans: Prelim